BNO.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Aug 2023 @ 00:34):

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers...

Stats
Today's Volume	4.41M
Average Volume	2.86M
Market Cap	13.22M
EPS	$0 ( 2024-02-21 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.450
ATR14	$0.00300 (30.00%)

Volume Correlation

Long: -0.41 (neutral)

Short: 0.00 (neutral)

Signal:(42.46) Neutral

Bionomics Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bionomics Ltd Correlation - Currency/Commodity

-0.48
( neutral )

-0.28
( neutral )

0.00
( neutral )

-0.18
( neutral )

-0.02
( neutral )

Bionomics Ltd Financials

Annual	2022
Revenue:	$22 047.00
Gross Profit:	$22 047.00 (100.00 %)
EPS:	$0

Q1	2021
Revenue:	$11 666.00
Gross Profit:	$11 665.50 (100.00 %)
EPS:	$-0.00322

Q4	2020
Revenue:	$11 666.00
Gross Profit:	$11 665.50 (100.00 %)
EPS:	$-0.00322

Q3	2020
Revenue:	$11 666.00
Gross Profit:	$11 665.50 (100.00 %)
EPS:	$-0.00322

Financial Reports:

No articles found.

Bionomics Ltd

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.